Clinical trialNARecruiting
Molecular Detection of Advanced Neoplasia in Pancreatic Cysts
Molecular Detection of Advanced Neoplasia in Pancreatic Cysts (IN-CYST)
- Outcome
- Ongoing
- Phase
- NA
- Status
- Recruiting
- Study type
- Interventional
- Start
- 11 May 2018
- Expected end
- 30 December 2030
- Enrollment
- 800 participants
- Sites
- 1
- Primary outcomes
- Biospecimen Acquisition; High grade dysplasia (HGD) or cancer diagnosis in Immediate Surgery group
- Sponsor
- Other
- Results posted
- No
- Last update
- 2 June 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Researchers are trying to find out whether new tests ("biomarkers") of blood, stool, pancreas cyst fluid, or pancreas juice can be used to diagnose malignant or pre-malignant changes in pancreas cysts.
Detailed description public domain (ClinicalTrials.gov)
Subjects with Fukuoka Worrisome (FW) or Fukuoka High Risk (FHR) pancreatic cysts will be enrolled and assigned to Immediate Surgery or Clinical Follow-up groups based on clinical management as determined by the treating physicians. Blood, stool, pancreas cyst fluid, and pancreas juice specimens will be collected from participants.